Skip to content
CancerIndex

Publication

Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.

Authors not recorded

Am J Hematol2013PMID 23861105stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23861105
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
U2AF1 Q157P/R1
(prognostic)Myelodysplastic SyndromeCURATED_BROADERPrognosticBSupports Poor Outcome3accepted
EID400

After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.

PMID 23861105 · Wu et al., 2013 · Open in CIViC

civic
U2AF1 S34Y/F1
(prognostic)Myelodysplastic SyndromeCURATED_BROADERPrognosticBSupports Poor Outcome3accepted
EID401

After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.

PMID 23861105 · Wu et al., 2013 · Open in CIViC

civic